Preferred Label : Ontorpacept;
NCIt synonyms : SIRPaFc; SIRPa-Fc Fusion Protein TTI-621;
NCIt definition : A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47
binding domain of human signal-regulatory protein alpha (SIRPa) linked to the Fc domain
of human immunoglobulin G1 (IgG1), with potential immune checkpoint inhibitory and
antineoplastic activities. Upon administration, ontorpacept selectively targets and
binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous
SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated
signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation
and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by
the binding of calreticulin (CRT), which is specifically expressed on the surface
of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1),
expressed on macrophages, and results in macrophage activation and the specific phagocytosis
of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated
antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed
on the surface of a variety of cancer cells. Expression of CD47, and its interaction
with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells
from phagocytosis, thereby allowing cancer cells to proliferate.;
UNII : Q8A4U1Z9N2;
CAS number : 2131089-46-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2131089-46-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : TTI 621; TTI-621;
NCI Metathesaurus CUI : CL504374;
Origin ID : C125718;
UMLS CUI : C5418174;
See also inter- (CISMeF)
- TTI-621 [MeSH Supplementary Concept]
- Semantic type(s)
- UMLS correspondences (same concept)
- TTI-621 [MeSH Supplementary Concept]
- concept_is_in_subset
- has_target
